In mice implanted with a patient-derived tumor containing an EGFR exon 20 activating insertion, or with engineered Ba/F3 cells containing a HER2 exon 20 activating insertion, once daily oral dosing of Mobocertinib induced regression of tumors at doses that were well tolerated (30-100 mg/kg)[1].
濟南深麗康化工科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook，有助于交易順利完成！
濟南深麗康